Kamada (NASDAQ:KMDA) Issues Quarterly Earnings Results, Misses Expectations By $0.05 EPS

Kamada (NASDAQ:KMDA) posted its earnings results on Wednesday. The biotechnology company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.05), FiscalAI reports. The business had revenue of $45.24 million for the quarter, compared to analysts’ expectations of $46.72 million. Kamada had a return on equity of 7.69% and a net margin of 11.21%.

Here are the key takeaways from Kamada’s conference call:

• Kamada reiterated full-year 2026 guidance for $200 million-$205 million in revenue and $50 million-$53 million in adjusted EBITDA, saying the outlook is based on organic growth only and implies stronger results in the back half of the year.
• First-quarter revenue was $42.5 million, up 3% year over year, with growth driven mainly by KEDRAB and the distribution segment. A temporary shipment delay reduced Q1 revenue by about $2.4 million, but the order was already delivered in April.
• Management said demand remains strong for key products, especially KEDRAB, which is seeing increased end-user utilization in the U.S. and international markets, and VARIZIG, which is benefiting from product awareness and more chickenpox outbreaks.
• The company is expanding its distribution and biosimilars business, with two additional biosimilars expected to launch in Israel by late Q2/early Q3 and a target of roughly 45 products in the Israeli portfolio by year-end. Management also expects biosimilar sales could reach $15 million-$20 million annually over the next four to five years.
• Kamada said its newly FDA-approved San Antonio plasma center is cleared to begin commercial normal source plasma sales in the second half of 2026, and both the Houston and San Antonio centers are expected to reach planned capacity toward end-2027/early-2028. The company also noted it remains active on business development and M&A to add products and synergies.

Kamada Price Performance

Shares of NASDAQ:KMDA traded up $0.16 during trading on Thursday, reaching $8.02. The company had a trading volume of 68,051 shares, compared to its average volume of 48,621. The firm has a market capitalization of $461.23 million, a price-to-earnings ratio of 22.91, a price-to-earnings-growth ratio of 0.61 and a beta of 0.86. The stock’s fifty day moving average price is $8.43 and its 200 day moving average price is $7.89. Kamada has a fifty-two week low of $6.50 and a fifty-two week high of $9.35.

Kamada Announces Dividend

The business also recently announced an annual dividend, which was paid on Tuesday, April 7th. Stockholders of record on Monday, March 23rd were issued a $0.25 dividend. The ex-dividend date of this dividend was Monday, March 23rd. This represents a dividend yield of 305.0%. Kamada’s payout ratio is presently 54.29%.

Institutional Trading of Kamada

A number of institutional investors have recently modified their holdings of KMDA. Cubist Systematic Strategies LLC purchased a new stake in shares of Kamada in the first quarter valued at approximately $206,000. NewEdge Advisors LLC boosted its stake in shares of Kamada by 119.9% in the first quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company’s stock valued at $341,000 after buying an additional 28,165 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in shares of Kamada in the first quarter valued at approximately $497,000. Jane Street Group LLC purchased a new stake in shares of Kamada in the first quarter valued at approximately $582,000. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of Kamada in the second quarter valued at approximately $472,000. 20.38% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on KMDA shares. Stifel Nicolaus set a $11.00 target price on Kamada in a research note on Wednesday, March 11th. Benchmark restated a “buy” rating on shares of Kamada in a research note on Thursday, March 12th. Weiss Ratings restated a “buy (b-)” rating on shares of Kamada in a research note on Thursday, January 22nd. Finally, Wall Street Zen lowered Kamada from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 14th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Kamada currently has an average rating of “Buy” and an average price target of $13.00.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma?derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha?1 antitrypsin augmentation therapy approved by the U.S.